Moderna-Merck Melanoma Win Confirms Oncology Engine, Respiratory Hurdles Persist

What happened

Merck and Moderna announced that their Phase 3 INTerpath-001 trial met its primary endpoints of recurrence-free survival and distant metastasis-free survival in adjuvant melanoma, marking a major validation for the individualized neoantigen therapy. This positive readout aligns with the master report's expectation that melanoma Phase 3 data could arrive in 2026 and serve as a key catalyst for the oncology value engine. While the news confirms the partnership's scientific promise, the market had already assigned some credit to oncology milestones, so the impact on valuation may be tempered. The core respiratory business still faces unresolved near-term hurdles, including the delayed U.S. flu approval and lack of visible RSV order conversion under the EU framework. Overall, the development strengthens the long-term thesis but does not remove the need for evidence that regulatory wins translate into revenue.

Implication

The Phase 3 melanoma success provides a tangible proof point for Moderna's oncology partnership, which could become a durable second revenue stream. However, the company's valuation still hinges on converting respiratory approvals into contracted sales, and both U.S. flu launch timing and EU RSV procurement remain uncertain. The positive readout may reduce downside risk but does not yet justify a re-rating without further respiratory catalysts. Investors should look for public FDA approval of mFlusiva and concrete RSV purchase orders before adding aggressively. A more attractive entry point could emerge below $48 if respiratory catalysts stall, while a break above $68 would require both oncology and respiratory successes.

Thesis delta

The positive Phase 3 melanoma data validates the oncology pillar of the investment thesis, shifting the bull case probability upward modestly. However, the WAIT rating remains unchanged because respiratory revenue conversion is still unresolved and the stock already prices in some oncology success. The key watch items now shift to FDA flu approval and EU RSV order execution.